20/01/2017

Innovative Training Network: 15 PhD Positions in Spain, Portugal, Sweden, Israel, Ireland, and Slovenia

This job offer has expired


  • ORGANISATION/COMPANY
    TREATMENT ITN
  • RESEARCH FIELD
    Biological sciences
    Medical sciences
    Neurosciences
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
    Recognised Researcher (R2)
    Established Researcher (R3)
    Leading Researcher (R4)
  • APPLICATION DEADLINE
    28/02/2017 23:59 - Europe/Brussels
  • LOCATION
    Spain › Madrid
  • TYPE OF CONTRACT
    Permanent
  • JOB STATUS
    Full-time

European training Network for “Metabolic Dysfunctions associated with Pharmacological Treatment of Schizophrenia” (H2020-MSCA-ITN-721236) offers 15 PhD positions located in Spain, Portugal, Sweden, Israel, Slovenia and Ireland. The MSCA programme offers a highly competitive and attractive salary and working conditions to Early Stage Researcher (ESR) or 0-4 years (Post Graduate). Completion of a Master Programme is not required for application but, the applicants should have a Master degree European training Network for “Metabolic Dysfunctions associated with Pharmacological Treatment of Schizophrenia” (H2020-MSCA-ITN-721236) offers 15 PhD positions located in Spain, Portugal, Sweden, Israel, Slovenia and Ireland. The MSCA programme offers a highly competitive and attractive salary and working conditions to Early Stage Researcher (ESR) or 0-4 years (Post Graduate). Completion of a Master Programme is not required for application but, the applicants should have a Master degree granted before the 30th of September, 2017.

*PhD Projects*

ESR1 will analyze tissue-specificity of schizophrenia and antipsychotic drugs on insulin sensitivity in order to unravel the tissue specificity of the critical nodes of insulin signalling that are dysregulated by the schizophrenia per se or as a consequence of the impact of the pharmacological treatment with olanzapine/aripriprazol catabolism on whole body metabolic control.

The ESR will examine the selective modulation of the critical nodes of insulin signalling (IR, IRS1/2, PTP1B, Akt) during schizophrenia per se and under antipsychotic therapy and the impact on whole body glucose homeostasis and energy expenditure. We expect to find differences in insulin-sensitive cells and tissues from mice treated with drugs for short or long time-periods. Secondly, the ESR will conduct studies in genetically modified (GM) mice bearing tissue-specific insulin resistance (IRS2 KO) or hypersensitivity (PTP1B KO). This approach will be relevant for the design of combined therapies aimed to ameliorate metabolic disturbances linked to antipsychotic treatments.
Host: Instituto de Investigaciones Biomédicas “Alberto Sols”, IIBm (CSIC-UAM).
Supervisors: Professor Ángela M. Valverde and Dr. María Monsalve (For information on this lab and more detail of the project please see https://www.iib.uam.es/portal/ and contact avalverde@iib.uam.es or mpmonsalve@iib.uam.es ).

ESR2 will study the effect of antipsychotic drugs in the pancreas in order to analyze the impact of schizophrenia per se and its pharmacological treatment with olanzapine or aripiprazol in the molecular machinery that modulates the endocrine pancreas.
The ESR will study the effects of schizophrenia per se and its treatment with antipsychotic drugs in the endocrine pancreas. By using cellular models of pancreatic alpha and beta cells, we expect to unravel alterations in the molecular mechanisms of insulin/glucagon secretion and cell plasticity due to antipsychotic drugs. It is expected to find altered responses to gastrointestinal peptides, particularly GLP1R agonists. In the in vivo mouse models of schizophrenia or its pharmacological treatments, the ESR will analyse if and how islet morphometry may be altered together with increased ER stress (PERK, ATF6, IRE1α) and apoptosis (Bax/Bak, caspase-3), limiting the first and second phase of insulin secretion.
Host: Instituto de Investigaciones Biomédicas “Alberto Sols”, IIBm (CSIC-UAM).
Supervisors: Professor Ángela M. Valverde and Professor Francisco Abad (For information on this lab and more detail of the project please see https://www.iib.uam.es/portal/ and contact avalverde@iib.uam.es or francisco.abad@salud.madrid.org ).

ESR3 will evaluate Drug-induced mitochondrial dysfunction to unravel how antipsychotic drug catabolism in the liver alters mitochondrial activity, and how the ensuing modified activity of master transcriptional regulators controlling oxidative metabolism may led to general metabolic dysfunctions including fibrosis.
The ESR will study drug specific differences on mitochondrial activity, as well as different capacity of the model animals to cope with the alterations in mitochondrial activity. The ESR will analyse background and drug specific differences in the induction of mitochondrial biogenesis (PGC1α/, TFAM, SIRT3) as a compensatory response of the liver to mitochondrial dysfunction and in the capacity to fully recover mitochondrial function that if limited, would result in the accumulation of dysfunctional mitochondria and elevated ROS. The final aim of the study would be to determine how these limitations in the mitochondrial oxidative capacity contribute to long term metabolic dysfunctions following chronic drug administration.
Host: Instituto de Investigaciones Biomédicas “Alberto Sols”, IIBm (CSIC-UAM).
Supervisors: Dr. María Monsalve and Dr. Juan Cigudosa (For information on this lab and more detail of the project please see https://www.iib.uam.es/portal/ and contact mpmonsalve@iib.uam.es or jccigudosa@nimgenetics.com ).

ESR4 will analyze the role of mitochondrial dysfunction in drug-induced cardiovascular disease in order to evaluate to what extent drug induced mitochondrial dysfunction may result in the development of cardiovascular disease.
The ESR will evaluate the genetic basis for variability on drug induced mitochondrial dysfunction on cardiovascular disease. Mitochondrial dysfunction is associated with cardiovascular disease, hence the putative impact of drug induced mitochondrial dysfunction on the cardiovascular system will be studied analyzing both macrovascular and microvascular complications. To that end the ESR will test the effects of psychotropic drugs on endothelial dysfunction, atheroma plaque formation, angiogenesis and retinopathy.
Host: Instituto de Investigaciones Biomédicas “Alberto Sols”, IIBm (CSIC-UAM).
Supervisors: Dr. María Monsalve and Professor Santiago Lamas (For information on this lab and more detail of the project please see https://www.iib.uam.es/portal/ and contact mpmonsalve@iib.uam.es or slamas@cbm.csic.es ).

ESR5 will study the effects of the antipsychotic drugs on human adipose tissue insulin signalling, glucose and lipid metabolism.
The ESR will: i) Investigate the in vitro effects on glucose uptake in human adipose cells and its interactions with insulin signalling. ii) Elucidate the effects on lipolysis, lipid storage and the expression genes regulating lipid metabolism (including fatty acid synthesis and storage as well as oxidation).
The ESR will analyse alterations in insulin-stimulated glucose uptake, insulin signalling and lipid handling that may contribute to the development of insulin resistance following antipsychotic drug treatment. These may contribute to lipid deposition in other organs, such as liver and muscle, leading to dyslipidemia. These studies will provide biomarkers on drug induced metabolic dysfunction of the adipose tissue.
Host: Uppsala Universitet (Uppsala, Sweden)
Supervisors: Professor Jan Eriksson and Professor Angela M. Valverde (For information on this lab and more detail of the project please see http://katalog.uu.se/profile/?id=N13-487 and contact jan.eriksson@medsci.uu.se or avalverde@iib.uam.es ).

ESR6 will study drug-induced low-grade chronic inflammation in human adipose tissue including interaction with other tissues in order to investigate effects of antipsychotic drugs on adipose tissue hormones, adipokines and chemochines, inflammatory markers, and other factors of potential importance for the development of T2D and obesity.
Human volunteers will have short term drug treatment, and in vivo and in vitro analyses will be performed., Assessments will include changes in hormonal (adipokines, dopamine, cortisol) and inflammatory factors, eg lipid species (fatty acid profiles, eicosanoids, leukotrienes), cytokines (eg TNFα, IL6, IL1β) and immune cells in adipose tissue. These factors may contribute to low-grade systemic inflammation, changes in macrophage polarization, whole body insulin resistance, liver steatosis and pancreatic beta cell dysfunction. Furthermore, samples from healthy, prediabetic and type 2-diabetes subjects will be compared, to identify putative differences in the drug effects depending on the metabolic milieu.
Host: Uppsala Universitet (Uppsala, Sweden).
Supervisor: Professor Jan Eriksson (For information on this lab and more detail of the project please see http://katalog.uu.se/profile/?id=N13-487 and contact jan.eriksson@medsci.uu.se).

ESR7 will evaluate the integrative metabolic effects of antipsychotic treatment in a rat model in order to evaluate global alterations in metabolic fluxes induced by in vivo treatment with olanzapine or aripiprazol in a rat model.
The ESR will develop non-invasive methods for characterizing hepatic expression of albumin, ApoB100, ApoJ and PON-1 and to apply these to rats treated with anti-schizophrenic drugs. The ESR will aim to integrate these methods with established stable isotope tracer protocols for characterizing changes in intermediary metabolic fluxes in the rat model administered with anti-schizophrenic drugs. The ESR will evaluate alterations in the insulin-signalling pathway (IR, IRS1/2, AKT) in isolated fat cells, BAT, muscle and skin. The ESR will identify the best set of biomarkers (plasma and urinary metabolites/proteins) that are correlated with changes in drug-induced metabolic fluxes and changes in activation of insulin signalling mediators at the level of these tissues. Finally, the ESR will validate the predictive efficacy of these biomarkers with the development of insulin resistance and cardiovascular disease in a population of anti-schizophrenic drug users.
Host: Centre for Neuroscience and Cell Biology, CNC (Coimbra, Portugal).
Supervisors: Dr. John Jones and Dr. Eugenia Carvalho (For information on this lab see http://www.cnbc.pt/research/department_show.asp?iddep=1138 and for more project detail please contact john.griffith.jones@gmail.com or eugeniamlcarvalho@gmail.com ).

ESR8 will study the metabolic impact of antipsychotic drugs on the CNS and in the regulation of whole body metabolism (hypothalamic-periphery axis) in order to evaluate the alterations in behaviour and in hypothalamic neurogenesis, as well as the effects on glucose and lipid metabolism in peripheral tissues after in vivo treatment with olanzapine or aripiprazol in rodents.

Offer Requirements

Skills/Qualifications

Postgraduate - Master's degree

Work location(s)
1 position(s) available at
TREATMENT ITN
Spain
Madrid

EURAXESS offer ID: 173282
Posting organisation offer ID: 603589

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.